CHECKLIST FOR THE SAFEST USE OF DABIGATRAN, RIVAROXABAN & APIXABAN IN ATRIAL FIBRILLATION: INCLUSION & EXCLUSION CRITERIA

被引：0
|
作者：
Leong, Wendy A. [1 ,2 ]
机构：
[1] Burnaby Res Vancouver, Vancouver, BC, Canada
[2] Univ British Columbia Vancouver, Vancouver, BC, Canada
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2014年 / 89卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
180
引用
收藏
页码：E86 / E86
页数：1
相关论文
共 50 条
  • [1] Checklist For The Safest Use of Dabigatran, Rivaroxaban & Apixaban In Atrial Fibrillation: Inclusion & Exclusion Criteria
    Leong, Wendy A.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 35 (03) : 412 - 412
  • [2] An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
    Mantha, Simon
    Ansell, Jack
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (03) : 476 - 484
  • [3] Direct Comparisons of Apixaban, Dabigatran and Rivaroxaban in Atrial Fibrillation
    Jansson, Martin U.
    Sjogren, Vilhelm
    Sjalander, Sara
    Renlund, Henrik
    Norrving, Bo
    Sjalander, Anders
    CIRCULATION, 2018, 138
  • [4] Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation
    Rillig, Andreas
    Lin, Tina
    Plesman, Joaquina
    Heeger, Christian-H.
    Lemes, Christine
    Metzner, Andreas
    Mathew, Shibu
    Wissner, Erik
    Wohlmuth, Peter
    Ouyang, Feifan
    Kuck, Karl-Heinz
    Tilz, Roland Richard
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2016, 27 (02) : 147 - 153
  • [5] Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban
    Giorgi, Mariano A.
    Cohen Arazi, Hernan
    Gonzalez, Claudio D.
    Di Girolamo, Guillermo
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (04) : 567 - 577
  • [6] New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation
    Aguilar, Maria I.
    Kuo, Ruth S.
    Freeman, William D.
    NEUROLOGIC CLINICS, 2013, 31 (03) : 659 - +
  • [7] Dabigatran but not rivaroxaban or apixaban reduces fibrinolytic resistance in patients with atrial fibrillation
    Ammollo, C. T.
    Semeraro, F.
    Incampo, F.
    Dellanoce, C.
    Paoletti, O.
    Testa, S.
    Colucci, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 118 - 118
  • [8] COST EFFECTIVENESS OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR ATRIAL FIBRILLATION IN GUATEMALA
    Garita, M.
    Peralta, M.
    Gordillo, D., I
    VALUE IN HEALTH, 2014, 17 (03) : A115 - A115
  • [9] PHARMACOECONOMIC ANALYSIS OF DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION: COMPARISON WITH RIVAROXABAN OR APIXABAN
    Gay-Molina, J. G.
    Herran, S.
    Sorensen, S.
    Gonschior, A. K.
    VALUE IN HEALTH, 2014, 17 (03) : A115 - A115
  • [10] Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation
    Noseworthy, Peter A.
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    McBane, Robert D.
    Shah, Nilay D.
    CHEST, 2016, 150 (06) : 1302 - 1312
12345